Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) was down 0.9% during trading on Friday . The stock traded as low as $13.08 and last traded at $13.29, with a volume of 109,648 shares changing hands. The stock had previously closed at $13.41.

Several equities research analysts have commented on PRTK shares. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Paratek Pharmaceuticals in a research note on Wednesday, April 6th. Zacks Investment Research downgraded shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 22nd. HC Wainwright reaffirmed a “buy” rating on shares of Paratek Pharmaceuticals in a research note on Monday, May 16th. Leerink Swann reaffirmed a “buy” rating and issued a $35.00 target price on shares of Paratek Pharmaceuticals in a research note on Sunday, May 15th. Finally, Robert W. Baird started coverage on shares of Paratek Pharmaceuticals in a research note on Friday, May 13th. They issued an “outperform” rating and a $30.00 target price for the company. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $35.67.

The company’s market capitalization is $235.76 million. The firm’s 50-day moving average is $15.01 and its 200-day moving average is $15.12.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its earnings results on Monday, May 2nd. The specialty pharmaceutical company reported ($1.77) EPS for the quarter, missing the consensus estimate of ($1.25) by $0.52.

In other Paratek Pharmaceuticals news, CEO Michael Bigham bought 20,000 shares of the business’s stock in a transaction that occurred on Thursday, June 23rd. The shares were acquired at an average cost of $13.45 per share, for a total transaction of $269,000.00. Following the transaction, the chief executive officer now directly owns 100,000 shares in the company, valued at $1,345,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Fund Iv L.P. Omega bought 461,538 shares of the business’s stock in a transaction that occurred on Monday, June 27th. The shares were acquired at an average price of $13.00 per share, for a total transaction of $5,999,994.00. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Paratek Pharmaceuticals stock. Turner Investments L.P. raised its stake in Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) by 16.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 61,430 shares of the specialty pharmaceutical company’s stock after buying an additional 8,710 shares during the period. Turner Investments L.P. owned 0.35% of Paratek Pharmaceuticals worth $1,165,000 at the end of the most recent quarter.

Paratek Pharmaceuticals, Inc (Paratek), formerly Transcept Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.